GALT Galectin Therapeutics
- 2.925
- +0.085+2.99%
Galectin Therapeutics News
Express News | Galectin Therapeutics Inc: Navigate Trial Remains on Track for Interim Top-Line Readout Late in Q4 of 2024
Express News | As Of March 31, 2024, Galectin Therapeutics Had $23.6M Of Cash And Cash Equivalents. Additionally, The Company Has $10M Remaining Available Under A $60M Line Of Credit Expected To Provide Cash Runway Into May 2025
Express News | Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Express News | Galectin Therapeutics Q1 Net Income USD -11.489 Million
Express News | Galectin Therapeutics Q1 EPS USD -0.19
Express News | Galectin Therapeutics Q1 Operating Income USD -9.648 Million
Press Release: Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update -- Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the con
Galectin Therapeutics Had $23.6M of Cash and Cash Equivalents at March 31 >GALT
Galectin Therapeutics Had $23.6M of Cash and Cash Equivalents at March 31 >GALT
Express News | Galectin Therapeutics Q1 2024 GAAP EPS $(0.19) Misses $(0.16) Estimate
Express News | Galectin Therapeutics Inc- Qtrly Shr Loss $0.19
Express News | Galectin Therapeutics - Believes It Has Sufficient Cash to Fund Currently Planned Operations, Research and Development Activities Through May 15, 2025
Galectin Therapeutics | 10-Q: Quarterly report
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be at
Galectin Therapeutics(GALT.US) Director Buys US$3,520 in Common Stock
$Galectin Therapeutics(GALT.US)$ Director Zordani Richard A. Jr. purchased 1,000 shares of common stock on Apr 30, 2024 at an average price of $3.52 for a total value of $3,520.Source: Announcement Wh
Galectin Therapeutics(GALT.US) Officer Buys US$3,390 in Common Stock
$Galectin Therapeutics(GALT.US)$ Officer LEWIS JOEL purchased 1,000 shares of common stock on Apr 24, 2024 at an average price of $3.39 for a total value of $3,390.Source: Announcement What is stateme
Galectin Therapeutics(GALT.US) 10% Shareholder Sells US$76,500 in Common Stock
$Galectin Therapeutics(GALT.US)$ 10% Shareholder CZIRR JAMES C sold 25,000 shares of common stock on Apr 22, 23, 2024 at an average price of $3.06 for a total value of $76,500.Source: Announcement(one
Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in
Galectin Therapeutics(GALT.US) Director Buys US$7,450 in Common Stock
$Galectin Therapeutics(GALT.US)$ Director FREEMAN KEVIN D purchased 2,500 shares of common stock on Apr 22, 2024 at an average price of $2.98 for a total value of $7,450.Source: Announcement What is s
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inogen (INGN) and Galectin Therapeutics (GALT)
Analysis
Price Target
No Data
